Can Cosentyx Users Get Vaccines?
Patients on Cosentyx (secukinumab), an IL-17 inhibitor for psoriasis, psoriatic arthritis, and ankylosing spondylitis, can receive most vaccines, but live vaccines are contraindicated due to infection risk. The prescribing information advises against live attenuated vaccines like MMR, varicella, or nasal flu spray while on treatment and for up to 4-6 months after stopping.[1]
Which Vaccines Are Recommended?
Inactivated or recombinant vaccines are safe and encouraged:
- COVID-19 vaccines (e.g., Pfizer, Moderna mRNA; J&J viral vector).
- Influenza (injectable, not nasal).
- Tdap, pneumococcal, shingles (Shingrix, recombinant).
- HPV, hepatitis B.
Healthcare providers should administer these before starting Cosentyx if possible, and boosters as scheduled. Responses may be reduced, so antibody testing can confirm immunity.[1][2]
Why Avoid Live Vaccines?
Cosentyx suppresses immune responses, increasing risks of disseminated infection from live vaccines. Case reports show complications like varicella reactivation in similar biologics. Wait at least 4 weeks after vaccination before starting Cosentyx.[1]
Timing Around Treatment Changes
- Before starting: Complete live vaccines 4+ weeks prior.
- During treatment: Stick to non-live; monitor for infections.
- After stopping: Delay live vaccines 4-6 months; evidence is limited, so consult immunology.[1][3]
COVID-19 Specifics for Cosentyx
All major COVID vaccines are non-live and recommended, even on biologics. Studies show slightly lower antibody responses (e.g., 10-20% reduced seroconversion vs. healthy controls), but real-world effectiveness holds, especially with boosters. CDC and EULAR endorse vaccination regardless.[2][4]
Patient Concerns and Real-World Advice
Common questions include shingles risk (higher on biologics; prioritize Shingrix) and travel vaccines (non-live OK). Infections occurred in 1-3% of Cosentyx trials, mostly mild. Discuss with rheumatologist or dermatologist for personalized plans, including TB screening pre-treatment.[1][3]
[1]: Cosentyx Prescribing Information (Novartis)
[2]: CDC Guidance on Immunocompromised Patients and COVID-19 Vaccines
[3]: EULAR Recommendations for Vaccination in Adult Patients with Rheumatic Diseases
[4]: Studies on Vaccine Response in IL-17 Inhibitors (e.g., Rheumatology Journal)